ZLDI-8 是一种 Notch 激活/切割酶 ADAM-17 抑制剂，可抑制 Notch 蛋白的切割。 ZLDI-8 降低促存活/抗凋亡和上皮间质转化 (EMT) 相关蛋白的表达。 ZLDI-8 还是一种竞争性且不可逆的酪氨酸磷酸酶 (Lyp) 抑制剂，IC50 为 31.6 μM，Ki 为 26.22 μM。 ZLDI-8 抑制 MHCC97-H 细胞的生长，IC50 为 5.32 μM。
货号:ajcx11534
CAS:667880-38-8
分子式:C??H??N?O?S
分子量：433.52
溶解度:62.5 mg/mL in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32?μM[1][2].参考文献：
[1]. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743.
[2]. Hou X, et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014 Nov 26;57(22):9309-22.